VivoSeq
Other

Bone

1

Pipeline Programs↗

15

Active Trials↗

11

Companies Involved↗

Bone is an early-stage landscape with 1 program across 11 companies. The most active players are Sanofi, Pfizer, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalG

Galena Biopharma, Inc.

0 programs

PreclinicalEisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Matched Placebo (capsules)

Creighton University

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

87

clinical trials

Completed53 · 61%
Unknown status13 · 15%
Recruiting5 · 6%
Not yet recruiting5 · 6%
Terminated4 · 5%
Active, not recruiting3 · 3%
Other4 · 5%

Clinical Trials

Trial Activity

87 trials

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy
Recruiting·RRush University Medical Center·N/A·NCT02582489·100 enrolled
Comparison of Flapless Immediate Implant Placement With Titanium Mesh Versus Immediate Implants Placement With Collagen Membrane in Type II Socket: A Randomized Clinical Trial
Recruiting·MMisr International University·Preclinical·NCT06875830·20 enrolled
Precision and Reliability of Dual X-ray Absorptiometry (DXA) Testing
Recruiting·PPenn State University·N/A·NCT03621306·400 enrolled
Effect of Calcium and Vitamin D Supplements and/or Prunes on Bone Health
Recruiting·San Diego State University·Preclinical·NCT06184646·200 enrolled
Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions Whose Malignant Origin Cannot be Excluded on Conventional Imaging
Recruiting·CCentral Hospital, Nancy, France·Preclinical·NCT05934994·68 enrolled
Resorbable vs Non-resorbable Bone Substitute at Immediate Post-extractive Single Implants
Active, not recruiting·—·Phase 3·NCT07047131·50 enrolled
BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement
Active, not recruiting·—·N/A·NCT07240493·24 enrolled
Boost Brittle Bones Before Birth
Active, not recruiting·KKarolinska Institutet·Phase 1/2·NCT03706482·18 enrolled
ALL Backbone in AYAs
Not yet recruiting·—·Phase 2·NCT07227584·67 enrolled
Hybrid Population Pharmacokinetic,Machine Learning and Deep Learning Modelling to Predict Dosing for the Individualization of Cyclosporine Therapy in Transplant Recipients
Not yet recruiting·YYasmin medhat munir Mohamed·N/A·NCT07695571·300 enrolled
Postprandial Regulation of Bone Perfusion in Healthy Individuals
Not yet recruiting·UUniversity of Copenhagen·Preclinical·NCT07679516·15 enrolled
Post-Market Clinical Follow-Up of the Osia System and Evaluation of Benefits of Transitioning From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients With Mixed or Conductive Hearing Loss
Not yet recruiting·CCochlear·Preclinical·NCT07130136·20 enrolled
Assessment of Vestibular Shifted Flap Versus Conventional Flap on Ridge Augmentation in Patients With Anterior Maxillary Bony Deficiency: a Randomized Control Trial
Not yet recruiting·CCairo University·Preclinical·NCT07664098·24 enrolled
Radiographic Assessment of Bone Dimension Around Immediate Implants With FDBA and I-PRF vs FDBA Alone
Enrolling by invitation·KKrishnadevaraya College of Dental Sciences & Hospital·Phase 2·NCT06522321·20 enrolled
Contribution of Bone to Urine Citrate
Enrolling by invitation·UUniversity of Texas Southwestern Medical Center·N/A·NCT06811363·25 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)